Ovarian hormone progesterone plays pivotal role in altering breast stem cells: PMH researchers

January 30, 2016

Adjusted net income for common shareholders for the first quarter of 2010 was $8.8 million, or $0.22 per share, compared to adjusted net loss for common shareholders of $5.6 million, or $0.14 per share, for the first quarter of the prior year. Adjusted net income (loss) for common shareholders excludes amortization of intangible assets, realized loss on marketable securities and non-cash stock compensation expense.

Company Highlights

According to IntrinsiQ data for March 2010, in all lines of metastatic breast cancer (MBC), ABRAXANE use represented 31.4 percent of the taxane market. In second line + MBC, ABRAXANE was 41.6 percent. ABRAXANE continues to be a leader in the taxane market in the third line + setting of the MBC market with a 47.6 percent market share. In March, Abraxis announced that the Phase 3 study in non-small cell lung cancer had achieved its primary endpoint of overall response rate. Details of the study data will be presented at the upcoming meeting of the ASCO. Abraxis announced updated overall survival findings from a Phase I/II study that explored the potential benefit of ABRAXANE in combination with gemcitabine for the first-line treatment of advanced pancreatic cancer. These findings were discussed during a keynote address by Daniel Von Hoff, M.D. of the Translational Genomics Research Institute (TGen) at the 101st Annual Meeting of the American Association for Cancer Research (AACR). Also presented at AACR were the results of a pre-clinical study of ABRAXANE given in combination with bevacizumab, which demonstrated that the combination may have potential in the treatment of triple-negative breast cancers.

SOURCE Abraxis BioScience, Inc.